Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations

Mattia Galli, Francesco Franchi, Fabiana Rollini, Larisa H. Cavallari, Davide Capodanno, Filippo Crea, Dominick J. Angiolillo

Research output: Contribution to journalReview articlepeer-review


Introduction: Clopidogrel is the most frequently utilized P2Y12 inhibitor and is characterized by broad interindividual response variability resulting in impaired platelet inhibition and increased risk of thrombotic complications in a considerable number of patients. The potent P2Y12 inhibitors, prasugrel and ticagrelor, can overcome this limitation but at the expense of an increased risk of bleeding. Genetic variations of the cytochrome P450 (CYP) 2 C19 enzyme, a key determinant in clopidogrel metabolism, have been strongly associated with clopidogrel response profiles prompting investigations of genetic-guided selection of antiplatelet therapy. Areas covered: The present manuscript focuses on the rationale for the use of genetic testing to guide the selection of platelet P2Y12 inhibitors among patients undergoing percutaneous coronary intervention (PCI). Moreover, a comprehensive appraisal of the available evidence and practical recommendations is provided. Expert Commentary: Implementation of genetic testing as a strategy to guide the selection of therapy can result in escalation (i.e. switching to prasugrel or ticagrelor) or de-escalation (i.e. switching to clopidogrel) of P2Y12 inhibiting therapy. Most recent investigations support the clinical benefit of a genetic guided selection of antiplatelet therapy in patients undergo PCI. Integrating the results of genetic testing with clinical and procedural variables represents a promising strategy for a precision medicine approach for the selection of antiplatelet therapy among patients undergoing PCI.

Original languageEnglish
Pages (from-to)963-978
Number of pages16
JournalExpert Review of Clinical Pharmacology
Issue number8
Publication statusPublished - 2021


  • antiplatelet therapy
  • bleeding
  • Genetics
  • p2y inhibitors
  • percutaneous coronary intervention
  • thrombosis

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations'. Together they form a unique fingerprint.

Cite this